PI-88 and Novel Heparan Sulfate Mimetics Inhibit Angiogenesis

 

 Buy Article Permissions and Reprints

ABSTRACT

The heparan sulfate (HS) mimetic PI-88 is a promising inhibitor of tumor growth and metastasis expected to commence phase III clinical evaluation in 2007 as an adjuvant therapy for postresection hepatocellular carcinoma. Its anticancer properties are attributed to inhibition of angiogenesis via antagonism of the interactions of angiogenic growth factors and their receptors with HS. It is also a potent inhibitor of heparanase, an enzyme that plays a key role in both metastasis and angiogenesis. A series of PI-88 analogs have been prepared with enhanced chemical and biological properties. The new compounds consist of single, defined oligosaccharides with specific modifications designed to improve their pharmacokinetic properties. These analogs all inhibit heparanase and bind to the angiogenic fibroblast growth factor 1 (FGF-1), FGF-2, and vascular endothelial growth factor with similar affinity to PI-88. However, compared with PI-88, some of the newly designed compounds are more potent inhibitors of growth factor-induced endothelial cell proliferation and of endothelial tube formation on Matrigel. Representative compounds were also tested for antiangiogenic activity in vivo and were found to reduce significantly blood vessel formation. Moreover, the pharmacokinetic profile of several analogs was also improved, as evidenced primarily by lower clearance in comparison with PI-88. The current data support the development of HS mimetics as potent antiangiogenic anticancer agents.

REFERENCES

• 1 Carmeliet P, Jain R K. Angiogenesis in cancer and other diseases.  Nature. 2000;  407 249-257
  CrossrefPubMedGoogle Scholar
• 2 Bergers G, Benjamin L E. Tumorigenesis and the angiogenic switch.  Nat Rev Cancer. 2003;  3 401-410
  CrossrefPubMedGoogle Scholar
• 3 Herbst R S. Therapeutic options to target angiogenesis in human malignancies.  Expert Opin Emerg Drugs. 2006;  11 635-650
  CrossrefPubMedGoogle Scholar
• 4 Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer.  Nat Rev Cancer. 2002;  2 521-528
  CrossrefPubMedGoogle Scholar
• 5 Wegrowski Y, Maquart F X. Involvement of stromal proteoglycans in tumour progression.  Crit Rev Oncol Hematol. 2004;  49 259-268
  PubMedGoogle Scholar
• 6 Lever R, Page C P. Novel drug development opportunities for heparin.  Nat Rev Drug Discov. 2002;  1 140-148
  CrossrefPubMedGoogle Scholar
• 7 Presta M, Leali D, Stabile H et al.. Heparin derivatives as angiogenesis inhibitors.  Curr Pharm Des. 2003;  9 553-566
  CrossrefPubMedGoogle Scholar
• 8 Parish C R, Freeman C, Brown K J, Francis D J, Cowden W B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.  Cancer Res. 1999;  59 3433-3441
  PubMedGoogle Scholar
• 9 Cochran S, Li C, Fairweather J K et al.. Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance.  J Med Chem. 2003;  46 4601-4608
  CrossrefPubMedGoogle Scholar
• 10 Khachigian L M, Parish C R. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies.  Cardiovasc Drug Rev. 2004;  22 1-6
  PubMedGoogle Scholar
• 11 Hazel S J. A novel early chorioallantoic membrane assay demonstrates quantitative and qualitative changes caused by antiangiogenic substances.  J Lab Clin Med. 2003;  141 217-228
  CrossrefPubMedGoogle Scholar
• 12 Joyce J A, Freeman C, Meyer-Morse N, Parish C R, Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.  Oncogene. 2005;  24 4037-4051 , [Corrigenda in Oncogene 2005;24:4163]
  PubMedGoogle Scholar
• 13 Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.  Int J Biochem Cell Biol. 2006;  38 2018-2039
  CrossrefPubMedGoogle Scholar
• 14 Hammond E, Bytheway I, Ferro V. Heparanase as a target for anticancer therapeutics: new developments and future prospects. In: Delehedde M, Lortat-Jacob H New Developments in Therapeutic Glycomics. Kerala, India: Research Signpost 2006: 251-282
  Google Scholar
• 15 Demir M, Iqbal O, Hoppensteadt D A et al.. Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88).  Clin Appl Thromb Hemost. 2001;  7 131-140
  PubMedGoogle Scholar
• 16 Yu G, Gunay N S, Linhardt R J et al.. Preparation and anticoagulant activity of the phosphosulfomannan PI-88.  Eur J Med Chem. 2002;  37 783-791
  CrossrefPubMedGoogle Scholar
• 17 Ferro V, Fewings K, Palermo M C, Li C. Large-scale preparation of the oligosaccharide phosphate fraction of Pichia holstii NRRL Y-2448 phosphomannan for use in the manufacture of PI-88.  Carbohydr Res. 2001;  332 183-189
  CrossrefPubMedGoogle Scholar
• 18 Ferro V, Li C, Fewings K et al.. Determination of the composition of the oligosaccharide phosphate fraction of Pichia (Hansenula) holstii NRRL Y-2448 phosphomannan by capillary electrophoresis and HPLC.  Carbohydr Res. 2002;  337 139-146
  CrossrefPubMedGoogle Scholar
• 19 Iversen P O, Sorensen D R, Benestad H B. Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias.  Leukemia. 2002;  16 376-381
  CrossrefPubMedGoogle Scholar
• 20 Rosenthal M A, Rischin D, McArthur G et al.. Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia.  Ann Oncol. 2002;  13 770-776
  CrossrefPubMedGoogle Scholar
• 21 Basche M, Gustafson D L, Holden S N et al.. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.  Clin Cancer Res. 2006;  12 5471-5480
  CrossrefPubMedGoogle Scholar
• 22 Gautam A M, Ferro V, Wilson E A, Freeman C, Parish C. PI-88, a heparanase inhibitor showing promising evidence of patient benefit in phase II clinical trials. Paper presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications November 14-18, 2005 Philadelphia, PA
  Google Scholar
• 23 Chen P, Chang S, Lai C, Gautam A, Wilson E. Use of PI-88, a novel heparanase inhibitor, as adjuvant therapy in post-resection hepatocellular carcinoma: a large randomised phase II clinical trial. Paper presented at: Shanghai-Hong Kong International Liver Congress March 25-28, 2006 Shanghai, China
  Google Scholar
• 24 Poon R T, Fan S T, Lo C M et al.. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis.  J Clin Oncol. 2000;  18 1094-1101
  PubMedGoogle Scholar
• 25 Karoli T, Liu L, Fairweather J K et al.. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88).  J Med Chem. 2005;  48 8229-8236
  CrossrefPubMedGoogle Scholar
• 26 Nyberg K, Ekblad M, Bergström T et al.. The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus.  Antiviral Res. 2004;  63 15-24
  CrossrefPubMedGoogle Scholar
• 27 Wood J M, Bold G, Buchdunger E et al.. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.  Cancer Res. 2000;  60 2178-2189
  PubMedGoogle Scholar
• 28 McCarty M F, Baker C H, Bucana C D, Fidler I J. Quantitative and qualitative in vivo angiogenesis assay.  Int J Oncol. 2002;  21 5-10
  PubMedGoogle Scholar

Vito FerroPh.D. 

Drug Design Group, Progen, Pharmaceuticals Ltd.

P.O. Box 2403, Toowong Qld 4066, Australia

Email: vito.ferro@progen-pharma.com.au